PATIENT-DERIVED XENOGRAFT (PDX) MODELS FOR EFFICACY SCREENING

BRING YOUR RESEARCH CLOSER TO CLINICS WITH MATCHING, WELL-CHARACTERIZED, AND SEQUENCED PDX MODELS.

Tumor heterogeneity is a challenge in cancer research and drug development. Sometimes, a comprehensive view of a tumor, tumor microenvironment, or their interaction is needed to understand your drug. This is when it is helpful to examine a patient derived xenograft (PDX) model matched to the selection of our PD3D models of tumors.

Explore our partner EPO's collection of highly-characterised PDX models 

AVAILABLE PDX MODELS

FOUNDED IN 1997, EPO DEVELOPS CUSTOMIZED IN VIVO TESTING PROCEDURES, SERVING MORE THAN 150 CLIENTS FROM BIG PHARMA TO ACADEMIA WORLD-WIDE.

A PDX model is typically implanted as fragment into immunodeficient mouse models. Usually, PDX models are treated with your lead compound and current standard of care chemo- or targeted therapy as control. Common read-out of these experiments is the tumor size as a measure for efficacy.

Other experimental setups include serial-dilution experiments to determine residual resistance and tumor engraftment frequency, which is the gold standard assay for cancer stem cell function.

HUMANIZED IMMUNE-ONCOLOGY MOUSE MODELS

The recent clinical success of immune checkpoint modulators has stimulated immune-oncology research leading to the identification of new tumor immunology targets. We offer new preclinical immune oncology models for target validation and drug development. We developed preclinical humanized mouse models where patient-derived xenografts from different tumor indications grow on mice with a functional human immune system. This strategy allows implementing the highly predictable PDX in a functional human immune environment for better drug efficacy and safety studies. Our humanized PDX models enable appropriate preclinical studies on tumor immune biology, evaluation of new immune therapies and combinations, as well as the identification and validation of biomarkers for tumor immune therapy.

EXPERIMENTAL PATHOLOGY AND HISTOPATHOLOGICAL SERVICES

EPO PROVIDES HIGH-QUALITY ANALYSIS OF TISSUES OBTAINED FROM EXPERIMENTAL SYSTEMS IN DIVERSE MAMMALIAN ORGANISMS IN PARTICULAR TO INVESTIGATORS WORKING WITH LABORATORY ANIMALS.

EPO has established a state-of-the-art histology/pathology laboratory and in-house expertise to provide you with a wide array of pathology services, histopathological consultation and interpretation of pathology services. EPO can provide high-quality analysis of tissues obtained from experimental systems in diverse mammalian organisms in particular to investigators working with laboratory animals.

  • necropsies
  • dissection and tissue processing including tissue fixation (frozen or fixed tissues)
  • preparation of sections from frozen or fixed samples
  • generation of stained or unstained slides
  • comprehensive sets of tissue-based tests and diagnostic services
  • immunohistochemistry

All xenograft models are exclusively performed at our partner company EPO

VISIT EPO ONLINE